PMID- 22933429
OWN - NLM
STAT- MEDLINE
DCOM- 20130606
LR  - 20221207
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 1
DP  - 2013 Jan
TI  - Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes 
      in Caucasians.
PG  - 145-9
LID - 10.2337/dc12-0703 [doi]
AB  - OBJECTIVE: The incidence of the metabolic syndrome and type 2 diabetes mellitus 
      (T2DM) is rising worldwide. Liver-derived fibroblast growth factor (FGF)-21 
      affects glucose and lipid metabolism. The aim of this study was to analyze the 
      predictive value of FGF-21 on the incidence of T2DM and the metabolic syndrome. 
      RESEARCH DESIGN AND METHODS: The Metabolic Syndrome Berlin Potsdam (MeSyBePo) 
      recall study includes 440 individuals. Glucose metabolism was analyzed using an 
      oral glucose tolerance test, including insulin measurements. FGF-21 was measured 
      using enzyme-linked immunosorbent assay. Primary study outcome was diabetes and 
      the metabolic syndrome incidence and change of glucose subtraits. RESULTS: During 
      a mean follow-up of 5.30 +/- 0.1 years, 54 individuals developed the metabolic 
      syndrome, 35 developed T2DM, and 69 with normal glucose tolerance at baseline 
      progressed to impaired glucose metabolism, defined as impaired fasting glucose, 
      impaired glucose tolerance, or T2DM. FGF-21 predicted incident metabolic syndrome 
      (lnFGF-21 odds ratio [OR] 2.6 [95% CI 1.5 - 4.5]; P = 0.001), T2DM (2.4 
      [1.2-4.7]; P = 0.01), and progression to impaired glucose metabolism (2.2 [1.3 - 
      3.6]; P = 0.002) after adjustment for age, sex, BMI, and follow-up time. 
      Additional adjustment for waist-to-hip ratio, systolic blood pressure, HDL 
      cholesterol, triglycerides, and fasting glucose did not substantially modify the 
      predictive value of FGF-21. CONCLUSIONS: FGF-21 is an independent predictor of 
      the metabolic syndrome and T2DM in apparently healthy Caucasians. These results 
      may indicate FGF-21 resistance precedes the onset of the metabolic syndrome and 
      T2DM.
FAU - Bobbert, Thomas
AU  - Bobbert T
AD  - Department of Endocrinology, Diabetes and Nutrition, Charite-Universitatsmedizin 
      Berlin, Berlin, Germany. thomas.bobbert@charite.de
FAU - Schwarz, Franziska
AU  - Schwarz F
FAU - Fischer-Rosinsky, Antje
AU  - Fischer-Rosinsky A
FAU - Pfeiffer, Andreas F H
AU  - Pfeiffer AF
FAU - Mohlig, Matthias
AU  - Mohlig M
FAU - Mai, Knut
AU  - Mai K
FAU - Spranger, Joachim
AU  - Spranger J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120828
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Biomarkers)
RN  - 0 (fibroblast growth factor 21)
RN  - 62031-54-3 (Fibroblast Growth Factors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers/*blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Fibroblast Growth Factors/*blood
MH  - Humans
MH  - Male
MH  - Metabolic Syndrome/*blood
MH  - Middle Aged
MH  - White People
MH  - Young Adult
PMC - PMC3526237
EDAT- 2012/08/31 06:00
MHDA- 2013/06/07 06:00
PMCR- 2014/01/01
CRDT- 2012/08/31 06:00
PHST- 2012/08/31 06:00 [entrez]
PHST- 2012/08/31 06:00 [pubmed]
PHST- 2013/06/07 06:00 [medline]
PHST- 2014/01/01 00:00 [pmc-release]
AID - dc12-0703 [pii]
AID - 0703 [pii]
AID - 10.2337/dc12-0703 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jan;36(1):145-9. doi: 10.2337/dc12-0703. Epub 2012 Aug 28.